Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Heterocyclic carbon compounds containing a hetero ring...
Reexamination Certificate
2005-01-18
2005-01-18
Bernhardt, Emily (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Heterocyclic carbon compounds containing a hetero ring...
C514S249000, C544S343000, C544S344000
Reexamination Certificate
active
06844345
ABSTRACT:
The present invention provides piperazine derivatives in accordance with formula (I)as well as salts, hydrates and esters thereof. The substituent designations are as provided in the specification. The compounds of the present invention can be used in the treatment of type II diabetes or obesity.
REFERENCES:
patent: 3317524 (1967-05-01), Freed
patent: 4598089 (1986-07-01), Hadvary et al.
patent: 5854245 (1998-12-01), Duggan et al.
patent: 6004996 (1999-12-01), Shah et al.
patent: 20030216401 (2003-11-01), Bentley et al.
patent: 185 359 (1986-06-01), None
patent: 189 577 (1986-08-01), None
patent: 443 449 (1991-08-01), None
patent: 524 495 (1993-01-01), None
patent: 0 572 863 (1993-12-01), None
patent: WO 9612721 (1996-05-01), None
patent: WO 9934786 (1999-07-01), None
patent: WO 0009122 (2000-02-01), None
patent: WO 0009123 (2000-02-01), None
patent: WO 0044753 (2000-08-01), None
patent: WO 0210169 (2002-02-01), None
Parker, “Obesity: Trends and Treatments”, Scrip Reports, PJB Publications Limited, (1996).
Kennett et al., Psychopharmacology, 96, pp. 93-100 (1988).
Kennett et al., Eur. J. Pharmacol., 141, pp. 429-435 (1987).
Kitchener et al., Psychopharmacology, 113, pp. 369-377 (1994).
Walsh et al., Psychopharmacology, 116, pp. 120-122 (1994).
Sargeant et al., Psychopharmacology, 133, pp. 309-312 (1997).
Tecott et al., Nature, vol. 374, pp. 542-546 (1995).
Kennett et al., Neuropharmacology, vol. 36, pp. 609-620 (1997).
Hoyer et al., European J. Pharmacology, 118, pp. 13-23 (1985).
Schmuck et al., FEBS Letters, 342, pp. 85-90 (1994).
McKenna et al., J. Neuroscience, 9, pp. 3482-3490 (1989).
Rajur et al., Indian J. Chem., 28B(12), pp. 1065-1068 (1989).
Yamada et al., Agr. Biol. Chem., 36(1), pp. 106-111 (1972).
Katritzky et al. (eds.), Best Synthetic Methods, Academic Press, London, pp. 105-134 (1996).
MacDougald et al., Current Biology, vol. 5, pp. 618-621 (1995).
Keller et al., Trends Endocrin. Metab., 4, pp. 291-296 (1993).
Gribble, J. Chem. Soc., Perkin I, pp. 1045-1075 (2000).
Bos et al., European Journal of Medicinal Chemistry, vol. 32, No. 3, 1997, pp. 253-261, XP004075426.
Grinev et al., Pharm. Chem. J., vol. 18, No. 2, 1984, pp. 94-98, XP001084869.
Andreeva et al., Pharm. Chem. J., vol. 30, No. 7, 1996, pp. 432-440, XP001084868.
Abstract corresponding to EP 0 572 863 (B1).
Gupta Y K et al., Indian Journal of Pharmacology, 1994, pp. 94-107, vol. 26, No. 2.
Hebeisen Paul
Mattei Patrizio
Muller Marc
Richter Hans
Roever Stephan
Bernhardt Emily
Hoffman-La Roche Inc.
Johnston George W.
Megerditchian Samuel H.
Tramaloni Dennis P.
LandOfFree
Piperazine derivatives does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Piperazine derivatives, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Piperazine derivatives will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3382148